A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
13 08 2019
13 08 2019
Historique:
received:
15
04
2019
accepted:
01
07
2019
entrez:
14
8
2019
pubmed:
14
8
2019
medline:
14
8
2019
Statut:
ppublish
Résumé
Multiple myeloma is, in most patients, an incurable cancer. Its precursors can be identified with routine tests setting the stage for early intervention to prevent active myeloma. We investigated the efficacy and safety of pembrolizumab, an antiprogrammed cell death 1 antibody, in smoldering myeloma patients with intermediate/high risk of progression to symptomatic myeloma. Thirteen patients were treated with a median number of 8 cycles. One patient achieved a stringent complete response with bone marrow next-generation sequencing negativity at 10
Identifiants
pubmed: 31405950
pii: bloodadvances.2019000300
doi: 10.1182/bloodadvances.2019000300
pmc: PMC6693011
doi:
Banques de données
ClinicalTrials.gov
['NCT02603887']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2400-2408Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2019 by The American Society of Hematology.
Références
Blood. 2007 Jul 1;110(1):296-304
pubmed: 17363736
Tissue Antigens. 2008 Mar;71(3):187-92
pubmed: 18179644
Blood Cancer J. 2012 Sep 07;2:e89
pubmed: 22961061
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Blood. 2013 Dec 19;122(26):4172-81
pubmed: 24144641
Blood. 2014 Jan 2;123(1):78-85
pubmed: 24144643
Cancer Cell. 2014 Jan 13;25(1):91-101
pubmed: 24434212
Leukemia. 2015 Oct;29(10):2110-3
pubmed: 25778100
Nat Commun. 2015 Apr 23;6:6997
pubmed: 25904160
Blood. 2015 Nov 26;126(22):2475-8
pubmed: 26468228
Nat Genet. 2015 Dec;47(12):1402-7
pubmed: 26551669
Blood. 2016 Jun 16;127(24):2955-62
pubmed: 27002115
J Clin Oncol. 2016 Aug 10;34(23):2698-704
pubmed: 27269947
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Eur J Cancer. 2017 Mar;74:55-72
pubmed: 28335888
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Leukemia. 2018 Jan;32(1):230-233
pubmed: 28832023
Blood Cancer J. 2017 Sep 22;7(9):e612
pubmed: 28937974
Blood Adv. 2017 Sep 29;1(22):1911-1918
pubmed: 29296837
Br J Haematol. 2018 Aug;182(4):495-503
pubmed: 29808907
Nat Med. 2018 Oct;24(10):1545-1549
pubmed: 30127394
JAMA Oncol. 2018 Dec 1;4(12):e183267
pubmed: 30128502
Nat Commun. 2018 Aug 22;9(1):3363
pubmed: 30135448
Gene. 2018 Dec 30;679:28-35
pubmed: 30171939
N Engl J Med. 2018 Nov 8;379(19):1791-1795
pubmed: 30403935
Front Immunol. 2018 Nov 16;9:2431
pubmed: 30505301